Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.57 |
| ▸ | ACLY | P53396 | 8/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | CCR4 | P51679 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24429550 | 0.84 | PTGES2 (0.53) | PTGES2ACLYALDH1A1SMN1; SMN2MCL1 | |
| SCHEMBL22088460 | 0.84 | ACLY (0.50) | PTGES2ACLYBRD4ALDH1A1SMN1; SMN2 | |
| SCHEMBL22034239 | 0.79 | SLC22A12 (0.55) | BRD4CCR4ALDH1A1GAASMN1; SMN2 | |
| SCHEMBL22088445 | 0.77 | ALOX15 (0.53) | PTGES2ACLYALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL30634113 | 0.76 | CCR4 (0.61) | CCR4 | |
| SCHEMBL20575754 | 0.76 | CCR4 (0.61) | CCR4 | |
| SCHEMBL29903808 | 0.76 | WDR5 (0.43) | PTGES2ACLYBRD4ALDH1A1FABP4 | |
| SCHEMBL26980267 | 0.76 | WDR5 (0.43) | PTGES2ACLYBRD4ALDH1A1FABP4 | |
| SCHEMBL30994034 | 0.76 | TSHR (0.58) | PTGES2ACLYALDH1A1POLBGAA | |
| SCHEMBL3771619 | 0.73 | PTGES2 (1.00) | PTGES2ACLYCCR4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649224-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649224-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649224-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2023-05-16 | — | — | US | disclosed |
| EP-3630748-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20210284628-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
| US-11021466-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200157079-A1 | IRE1 Small Molecule Inhibitors | QUENTIS THERAPEUTICS, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| EP-3630748-A1 | IRE1 SMALL MOLECULE INHIBITORS | Quentis Therapeutics, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20180346446-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2018-12-06 | — | — | US | disclosed |
| WO-2018222918-A1 | IRE1 SMALL MOLECULE INHIBITORS | QUENTIS THERAPEUTICS, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157079-A1 | IRE1 Small Molecule Inhibitors | XBP1, ERN2, ERN1 | PTGES2 2323/4885ACLY 3799/4885BRD4 495/4885 |
| US-11021466-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | PTGES2 2323/4885ACLY 3799/4885BRD4 495/4885 |
| US-20210284628-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | PTGES2 2323/4885ACLY 3799/4885BRD4 495/4885 |
| US-11649224-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | PTGES2 2323/4885ACLY 3799/4885BRD4 495/4885 |
| US-20180346446-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | PTGES2 2323/4885ACLY 3799/4885BRD4 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.